NASDAQ
Lyra Therapeutics, Inc. (LYRA) has a price/fcf ratio of -1.65x as of Tuesday, May 26, 2026. This represents a 98.42% increase compared to its 12-month average of -104.44x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.
No price data available for this timeframe.